drugset / Trial / NCT03389321
Clinical Study to Investigate Effect of Macitentan on Riociguat Pharmacokinetics
NaSingle-groupOpen-labelOther
Summary
Both macitentan and riociguat are indicated in the treatment of pulmonary arterial hypertension (PAH) and may be administered concomitantly. The primary objective of this study is to evaluate the effect of macitentan administered for 11 days on the pharmacokinetics (PK) (i.e., amount and time of presence in the blood of riociguat) of a single dose of riociguat in healthy male subjects.
Timeline
- Start
- 2018-01-09
- Primary completion
- 2018-02-06
- Completion
- 2018-02-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Macitentan | Other / unclassified | 10 mg | Oral |
| Subject | Riociguat | Other / unclassified | 1 mg | Oral |
Indications
No indication recorded.